{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-115850","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2024-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.175531+00:00","generated_at":"2026-05-30T02:52:01.389567+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Quoin Q3 net loss $2.3M; initiates Peeling Skin Syndrome study; management buys shares","bullets":["Net loss of $2.3M for Q3 2024 vs $1.9M in Q3 2023; nine-month net loss $6.7M vs $6.6M.","Cash and equivalents $10.3M as of Sept 30, 2024; expected to fund operations into late 2025.","Initiates investigator-led clinical study for QRX003 in Peeling Skin Syndrome in New Zealand; no approved treatments exist.","Opens two additional UK sites for Netherton Syndrome trials under FDA IND; plans further European expansion.","Entire management team made significant insider share purchases in September, signaling confidence in growth trajectory."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-115850","json":"https://secwatch.observer/filing/0001104659-24-115850.json","markdown":"https://secwatch.observer/filing/0001104659-24-115850.md","text":"https://secwatch.observer/filing/0001104659-24-115850.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465924115850/0001104659-24-115850-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465924115850/tm2427874d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:52:01.389567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}